Chemours (CC) PT Lowered to $39 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts CC Hot Sheet
Price: $13.41 -0.89%
Rating Summary:
7 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 25 | New: 16
Rating Summary:
7 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 25 | New: 16
Join SI Premium – FREE
BMO Capital analyst John McNulty lowered the price target on Chemours (NYSE: CC) to $39.00 (from $45.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $107 at Baird amid partial clinical hold
- Marvell (MRVL) PT Lowered to $275 at B.Riley
- Scorpio Tankers (STNG) PT Raised to $105 at Evercore ISI
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
